Fig. 1

miRNA expression profiling identified Nurr1-dependent signature miRNA in the inflammatory process of PD. A Expression heatmap of differential miRNA profiles in the PBMCs of HC (n = 5) and PD patients (n = 5) by miRNA sequencing, indicating significant disease-based clustering. B The representative KEEG terms of differentially expressed miRNAs in PD patients. C qRT-PCR was used to detect the expression levels of miR-21-5p, miR-30e-5p, miR-29a-5p and miR-105-5p in the PBMCs of PD patients (n = 42) and HC (n = 44). Data are presented as mean ± SEM. *p < 0.05, **p < 0.01. Unpaired Student T test. D qRT-PCR analysis of miR-21-5p, miR-30e-5p, miR-29a-5p and miR-105-5p in the stable Nurr1-knockdown RAW264.7 macrophage cells (ShNurr1-RAW) compared with the control RAW264.7 cells (ShNC-RAW). ****p < 0.0001. Unpaired Student T test. E Scatter plots of miR-30e-5p expression level in the PBMCs of HC (n = 226) and PD (n = 224). The effects of F H-Y staging, G duration of disease and H medication on the expression level of miR-30e-5p in PBMCs of PD patients. Horizontal bars represent mean and SEM values. **p < 0.01, ***p < 0.001, and ****p < 0.0001 by Unpaired Student T test. Rho, correlation coefficient by Spearman correlation analysis. DR DA receptor agonists monotherapy, l-dopa l-dopa monotherapy, l-dopa + DR the combination of DA agonists and l-dopa